Oncoloxía
Universidad Católica de Valencia San Vicente Mártir
Valencia, EspañaPublications in collaboration with researchers from Universidad Católica de Valencia San Vicente Mártir (2)
2023
2021
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394